A new study has identified variation in the gene SATB1 which has been shown to cause a rare genetic syndrome.
Advances in DNA sequencing have uncovered three classes of mutations within the gene SATB1, which result in three variations of a neurodevelopmental disorder with varying symptoms ranging from epilepsy to muscle tone abnormalities.
The study, co-authored by academics from Oxford Brookes University, University of Lausanne, Radboud University, University of Oxford, University of Manchester, and led by Max Planck Institute for Psycholinguistics (The Netherlands), identified 42 patients with mutations in the gene SATB1 who were all displaying a range of similar symptoms, with varying severity.
Identifying a new disorder
The newly identified SATB1-syndrome is characterised by neurodevelopmental delay, intellectual disability, muscle tone abnormalities, epilepsy, behavioural problems, facial dysmorphism, and dental abnormalities.
Dr Dianne Newbury, Senior Lecturer in Medical Genetics and Genomics at Oxford Brookes University said: “Previously, just one or two cases of patients with SATB1 variations had been described but it was not recognised as a specific syndrome. Patients displaying these characteristics and their families, will have known that they had an undefined neurological condition, but they wouldn’t have known any specific detail about the condition, or why they had it.
“We hope that the recognition of this new disorder, and the information about the molecular pathways contributing to it, will help the families and individuals affected understand more about the condition and achieve a diagnosis they would not have had previously.”
Effects in the cell
The mutations were found to belong to three different classes with the first mutation class causing a loss of function of the SATB1 gene and halving the production of the encoded protein, leading to a less severe syndrome characterised by diminished cognitive function, visual problems, and facial dysmorphism.
The second class of mutations encode shorter proteins that are less efficient, ad shows as an intermediary syndrome, characterised as more severe than the first, but less severe than the third.
The third class modify the encoded protein, making it more active. This altered protein is ‘sticky’ and binds better to DNA, diminishing the expression of genes it regulates and causing a more severe type of disorder, characterised by severe intellectual disability, epilepsy, a motor speech disorder (dysarthria) and specific facial features.
Dr Alexandre Reymond, Director of the Center for Integrative Genomics at the University of Lausanne in Switzerland said: “These results demonstrate that each mutation is different and that is essential to understand their mode of action in order to explain the origin of genetic diseases. We must go beyond sequencing, which is only a first step.”
The paper, ‘Mutation-specific pathophysiological mechanisms define different neurodevelopmental disorders associated with SATB1 dysfunction’, has been published in The American Journal of Human Genetics.
